#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	147	15690	16S	1529	1529	100.0	16S.l6.c4.ctg.1	2132	731.2	1	SNP	n	C1184T	0	.	.	1184	1184	C	1450	1450	C	936	C	873	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	147	15690	16S	1529	1529	100.0	16S.l6.c4.ctg.1	2132	731.2	0	HET	.	.	.	C451T	.	451	451	C	717	717	C	842	C,T	593,211	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	28538	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3548	801.6	0	.	n	.	0	T695C	SNP	695	695	T	1022	1022	C	854	C	792	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	28538	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3548	801.6	0	.	n	.	0	A1638G	SNP	1638	1638	A	1965	1965	G	939	G,A	662,231	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	28538	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3548	801.6	0	.	n	.	0	T1971C	SNP	1971	1971	T	2298	2298	C	844	C,A	791,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	28538	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3548	801.6	1	SNP	n	A2045G	0	.	.	2045	2045	A	2372	2372	A	902	A	864	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	28538	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3548	801.6	1	SNP	n	C2597T	0	.	.	2597	2597	C	2924	2924	C	927	C	879	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_V_01427c	folP.WHO_V_01427c	1	1	27	2126	folP	855	855	100.0	folP.l6.c4.ctg.1	1484	142.6	1	SNP	p	R229S	1	.	.	685	687	AGC	996	998	AGC	201;200;199	A;G;C	191;190;186	folP.WHO_V_01427c:1:1:R229S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	5602	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3265	170.7	1	SNP	p	S91F	1	.	.	271	273	TTC	524	526	TTC	170;174;172	T;T;C	163;165;164	gyrA.WHO_M_01098:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	5602	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3265	170.7	1	SNP	p	G95N	0	.	.	283	285	GGC	536	538	GGC	170;169;171	G;G;C	163;158;161	gyrA.WHO_M_01098:1:1:G95N:gyrA.95N:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	5602	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3265	170.7	1	SNP	p	D95G	1	.	.	283	285	GGC	536	538	GGC	170;169;171	G;G;C	163;158;161	gyrA.WHO_M_01098:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
mtrR.WHO_X_01389	mtrR.WHO_X_01389	1	1	27	1770	mtrR	633	633	100.0	mtrR.l6.c4.ctg.1	1322	133.1	1	SNP	p	G45D	0	.	.	133	135	GGC	505	507	GGC	221;219;220	G;G;C	211;205;204	mtrR.WHO_X_01389:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	862	mtrR_promoter	250	250	99.6	mtrR_promoter.l15.c30.ctg.1	1027	83.6	0	.	n	.	0	A197.	DEL	197	197	A	575	575	A	203	A	191	.	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	6074	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2989	202.3	1	SNP	p	D86N	0	.	.	256	258	GAC	663	665	GAC	261;259;259	G;A;C	243;241;243	parC.WHO_Y_00247c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	6074	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2989	202.3	1	SNP	p	S87R	1	.	.	259	261	CGT	666	668	CGT	261;255;255	C;G;T	244;240;239	parC.WHO_Y_00247c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	6074	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2989	202.3	1	SNP	p	R87I	0	.	.	259	261	CGT	666	668	CGT	261;255;255	C;G;T	244;240;239	parC.WHO_Y_00247c:1:1:R87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	6074	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2989	202.3	1	SNP	p	R87W	0	.	.	259	261	CGT	666	668	CGT	261;255;255	C;G;T	244;240;239	parC.WHO_Y_00247c:1:1:R87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	6074	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2989	202.3	1	SNP	p	S88P	0	.	.	262	264	TCC	669	671	TCC	256;256;252	T;C;C,T	235;237;233,1	parC.WHO_Y_00247c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	4492	parE	1986	1986	100.0	parE.l6.c30.ctg.1	2824	158.3	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1662	1664	GGC	202;195;193	G;G;C	186;182;174	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.34.001	penA.34.001	1	1	27	4178	penA	1746	1746	100.0	penA.l15.c30.ctg.1	2417	171.9	1	SNP	p	A311V	0	.	.	931	933	GCC	1281	1283	GCC	208;208;212	G;C;C	201;203;205	penA.34.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	4178	penA	1746	1746	100.0	penA.l15.c30.ctg.1	2417	171.9	1	SNP	p	I312M	1	.	.	934	936	ATG	1284	1286	ATG	210;208;206	A;T;G	203;200;197	penA.34.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	4178	penA	1746	1746	100.0	penA.l15.c30.ctg.1	2417	171.9	1	SNP	p	T316P	0	.	.	946	948	ACC	1296	1298	ACC	211;213;214	A,T;C;C	199,1;204;205	penA.34.001:1:1:T316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	4178	penA	1746	1746	100.0	penA.l15.c30.ctg.1	2417	171.9	1	SNP	p	V316T	1	.	.	946	948	ACC	1296	1298	ACC	211;213;214	A,T;C;C	199,1;204;205	penA.34.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	4178	penA	1746	1746	100.0	penA.l15.c30.ctg.1	2417	171.9	1	SNP	p	T483S	0	.	.	1447	1449	ACC	1797	1799	ACC	192;190;185	A;C;C	179;178;174	penA.34.001:1:1:T483S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	4178	penA	1746	1746	100.0	penA.l15.c30.ctg.1	2417	171.9	1	SNP	p	A501V	0	.	.	1501	1503	GCG	1851	1853	GCG	194;194;197	G,A;C;G	180,1;184;186	penA.34.001:1:1:A501V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	4178	penA	1746	1746	100.0	penA.l15.c30.ctg.1	2417	171.9	1	SNP	p	A501P	0	.	.	1501	1503	GCG	1851	1853	GCG	194;194;197	G,A;C;G	180,1;184;186	penA.34.001:1:1:A501P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	4178	penA	1746	1746	100.0	penA.l15.c30.ctg.1	2417	171.9	1	SNP	p	G542S	0	.	.	1624	1626	GGT	1974	1976	GGT	182;183;184	G;G;T	170;171;170	penA.34.001:1:1:G542S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	4178	penA	1746	1746	100.0	penA.l15.c30.ctg.1	2417	171.9	1	SNP	p	G545S	1	.	.	1633	1635	AGC	1983	1985	AGC	173;173;169	A,G;G;C	159,1;160;155	penA.34.001:1:1:G545S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	4178	penA	1746	1746	100.0	penA.l15.c30.ctg.1	2417	171.9	1	SNP	p	P551S	0	.	.	1651	1653	CCG	2001	2003	CCG	140;143;141	C,CGG;C,T;G,GGC	99,1;105,1;100,1	penA.34.001:1:1:P551S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	6134	ponA	2397	2397	100.0	ponA.l15.c4.ctg.1	3097	197.4	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1627	1629	CCG	220;219;219	C;C;G	198;203;200	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2608	porA	1146	1146	99.91	porA.l6.c4.ctg.1	1872	138.9	0	.	p	.	0	M83fs	FSHIFT	247	247	A	566	566	C	173	C	160	.	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	27	3238	porB1b	1038	1038	100.0	porB1b.l15.c4.ctg.1	1565	205.0	1	SNP	p	G120K	1	.	.	358	360	AAG	666	668	AAG	268;272;273	A;A;G,T	254;256;250,1	porB1b.WHO_Y_02277c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	27	3238	porB1b	1038	1038	100.0	porB1b.l15.c4.ctg.1	1565	205.0	1	SNP	p	A121N	1	.	.	361	363	AAC	669	671	AAC	276;273;271	A;A;C	258;257;256	porB1b.WHO_Y_02277c:1:1:A121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	27	3238	porB1b	1038	1038	100.0	porB1b.l15.c4.ctg.1	1565	205.0	1	SNP	p	N121D	0	.	.	361	363	AAC	669	671	AAC	276;273;271	A;A;C	258;257;256	porB1b.WHO_Y_02277c:1:1:N121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	11334	rpoB	4179	4179	99.98	rpoB.l15.c17.ctg.1	4995	226.3	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1348	rpsJ	312	312	100.0	rpsJ.l15.c30.ctg.1	1084	123.5	1	SNP	p	V57M	1	.	.	169	171	ATG	524	526	ATG	268;272;268	A;T;G	252;255;255	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
